Making a difference in people's lives by being a unique global pharmaceutical company driven by a disciplined
and performance based culture which values innovation, transparency and speed of execution.
Shionogi Inc.'s mission is "Working to deliver a better life". We develop and commercialize brand name
prescription products for niche opportunities within chronic disease markets.
05/07/2013: Shionogi Inc. Divests and exclusively licenses its pediatric products to Concordia Pharmaceuticals Inc.
Click Here to read more.
02/26/2013: Shionogi Receives FDA Approval for Osphena™ (ospemifene) tablets
Click Here to read more.
Click Here for Full Prescribing Information.
Deanne Melloy, Shionogi Inc.'s Executive Vice President and Chief Operating Officer, has been named one of New Jersey's 2013 Best 50 Women in Business
Click Here to read more.
Shionogi Inc, develops and commercializes pharmaceutical products. We have been providing innovative medicines essential to people's health for over 130 years.
Shionogi Inc.'s portfolio includes products for pain, pediatric conditions, cardiovascular disease, diabetes, and women's health.
Read about our latest approved product Osphena™.
Shionogi is dedicated to making a difference in patients' lives. Our Company has been providing medicines essential to people's health for over 130 years.
Press Releases
05/07/2013
Shionogi Inc. Divests and exclusively licenses its pediatric products to Concordia Pharmaceuticals Inc.
Read More >
02/26/2013
Shionogi Receives FDA Approval for OsphenaTM (ospemifene)
Read More >
01/08/2013
Shionogi & Co., Ltd. files patent infringement action in the U.S. District Court in New Jersey on December 28, 2012, regarding Sandoz’s submission of an Abbreviated New Drug Application with the FDA seeking approval for a generic version of Doribax(r)
Read More >